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Insulin-like growth factor-binding protein-3 (IGFBP-3), a
major regulator of endocrine actions of IGFs, is a p53-regulated
potent apoptotic factor and is significantly suppressed in a vari-
ety of cancers. Recent epidemiologic studies suggest that
IGFBP-3 contributes to cancer risk protection in a variety of
cancers, and a polymorphic variation of IGFBP-3 influences
cancer risk, although other studies vary in their conclusions.
Some antiproliferative actions of IGFBP-3 have been
reported to be independent of IGFs, but the precise biochem-
ical/molecular mechanisms of IGF-independent, antiprolif-
erative actions of IGFBP-3 are largely unknown. Here we
report a new cell death receptor, IGFBP-3R, that is a single-
span membrane protein and binds specifically to IGFBP-3
but not other IGFBP species. Expression analysis of IGFBP-3
and IGFBP-3R indicates that the IGFBP-3/IGFBP-3R axis is
impaired in breast and prostate cancer. We also provide evi-
dence for anti-tumor effect of IGFBP-3R in vivo using pros-
tate and breast cancer xenografts in athymic nude mice. Fur-
ther in vitro studies demonstrate that IGFBP-3R mediates
IGFBP-3-induced caspase-8-dependent apoptosis in various
cancer cells. Knockdown of IGFBP-3R attenuated IGFBP-3-
induced caspase activities and apoptosis, whereas overex-
pression of IGFBP-3R enhanced IGFBP-3 biological effects.
IGFBP-3R physically interacts and activates caspase-8, and
knockdown of caspase-8 expression or activity inhibited
IGFBP-3/IGFBP-3R-induced apoptosis. Here, we propose
that IGFBP-3R represents a novel cell death receptor and is
essential for the IGFBP-3-induced apoptosis and tumor sup-
pression. Thus, the IGFBP-3/IGFBP-3R axis may provide
therapeutic and prognostic value for the treatment of cancer.
Insulin-like growth factor-binding proteins (IGFBPs)3 are
integral components of the IGF system andmodulate biological
actions of IGFs such as cellular proliferation, differentiation,
increase in metabolic activity, and cell survival (1). Apart from
its ability to inhibit or enhance IGF actions, all the IGFBPs,
IGFBP-1 to -6, have been reported to exert distinct biological
actions such as cell proliferation, differentiation, migration,
angiogenesis, and apoptosis through an IGF/IGF-I receptor
(IGF-IR)-independentmanner (2–7). These intrinsic biological
activities of IGFBPs appear to be critical to cardiogenesis, vas-
cular development, and pathogenesis of cancer.
IGFBP-3, the most abundant IGFBP species in serum, circu-
lates as a 150-kDa ternary complex with an acid-labile subunit
and IGF peptide (1–3). Classically, the principal function of
IGFBP-3 has been to transport IGFs, protecting them from
rapid clearance and/or degradation, and modulating IGF bio-
availability to cell-surface IGF receptors (8–9). Many studies
have reported that IGFBP-3 exhibits distinct biological effects
independent of the IGF/IGF-IR axis, in particular cell growth
inhibition and induction of apoptosis in a variety of cancer cells
(10–14). IGFBP-3 was shown to exert its IGF/IGF-IR-inde-
pendent, antiproliferative actions via interaction with specific
proteins in the extracellular, cytoplasmic and nuclear compart-
ments of cancer cells, but the precise underlyingmechanisms of
IGFBP-3 have yet to be elucidated (12–16).
IGFBP-3 binding to a cell surface protein is indispensable
for its antiproliferative action in human breast cancer cells,
and the mid-region of IGFBP-3, which is the least conserved
region among the IGFBP-1-6 protein, is responsible for cell
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surface binding (17, 18). Moreover, IGFBP-3-induced apo-
ptosis through the activation of specific caspases that are
involved in the death receptor-mediated apoptotic pathways
in breast cancer cells (19). These findings strongly suggest
the existence of an IGFBP-3-specific receptor participating
in the direct proapoptotic effect of IGFBP-3 in cancer cells.
We describe herein the cloning and characterization of a
novel cDNA encoding a new cell death receptor for IGFBP-3,
IGFBP-3R. We found that IGFBP-3R is a bona fide IGFBP-3
receptor; IGFBP-3R is expressed on the cell surface, interacts
specifically with IGFBP-3, activates initiator caspase-8, and
mediates IGFBP-3-induced apoptosis in vitro and tumor sup-
pression in vivo.
EXPERIMENTAL PROCEDURES
Cell Culture—All cell lines, except M12 and the MCF-7:IG-
FBP-3 stable lines, were purchased from ATCC. We cultured
breast cancer cells inDulbecco’smodified Eagle’smedium/high
glucose with 10% fetal bovine serum (FBS), PC-3 in F-12 with
10% FBS, and M12 cells in RPMI 1640 medium supplemented
with 10 ng/ml epidermal growth factor, 0.02 mM dexametha-
sone, 5 g/ml insulin, 5 g/ml transferring, 5 g/ml selenium
and gentamicin at 37 °C under 5% CO2.MCF-7:IGFBP-3 stable
lines were generated from wild type MCF-7 cells using the
ecdysone-inducible expression system (Invitrogen). IGFBP-3
protein production was induced with the addition of ponaster-
one A (Invitrogen) to the culture medium.
Proteins and Antibodies—We purchased recombinant IGF-I
and IGFBP-1, -2, -4, -5, -6 from R&D Systems and AUSTRAL
Biologicals. We used anti-FLAG M2, GFP, -galactosidase,
-tubulin antibodies (Sigma-Aldrich), anti-caspase-3, caspase-8,
Fas-associated death domain protein (FADD), poly(ADP-ri-
bose) polymerase (PARP) antibodies (Cell Signaling Technolo-
gies), anti-CD34, histone deacetylases antibodies (Santa Cruz
Biotechnology), HRP-conjugated secondary antibodies (Amer-
sham Pharmacia), and fluorescently conjugated secondary
antibodies (Southern Biotechnology Associates and Molecular
Probes). Immunofluorescence-stained cells were visualized
with Alexa 488 or fluorescein isothiocyanate (Molecular
Probes).
Plasmids and Recombinant Proteins—pEGFP:IGFBP-3R was
generated by subcloning the IGFBP-3R cDNA into pEGFP-N3
(Clontech). GST::IGFBP-3R protein was generated by subclon-
ing the IGFBP-3R cDNA into the pGEX-4T-1 vector (Amer-
shamBiosciences) in-framewithGST, transforming into E. coli
strain BL21(DE3)pLysS, and inducing expression with isopro-
pyl 1-thio--D-galactopyranoside. Gel-purified protein from
cell lysates was injected into rabbits for polyclonal IGFBP-3R
antibody production.
Yeast Two-hybrid Screening—An Hs578T cDNA library in
pGAD10 was generated using the Two-Hybrid cDNA
Library Construction kit (Clontech). The bait plasmid was
constructed by amplifying an internal sequence of the
IGFBP-3 cDNA (encoding amino acids 88–148) by PCR,
then cloning this fragment into the pBTM116 vector, in-
frame with the LexA DNA binding domain coding sequence.
The bait plasmid was then transformed into yeast strain L40.
A single transformant colony was selected for successive
transformation with the pGAD10:Hs578T cDNA library.
663 transformant colonies that grew on selective media were
replica-plated onto duplicate fresh plates, one of which was
used for a -galactosidase assay. Positive colonies were then
cultured on non-selective media until the bait plasmid was
lost and further tested in mating assays with the original bait
strain and a false-positive screening strain expressing the
pBTM116:lamin plasmid. Three colonies tested positive
with the IGFBP-3 bait and negative with lamin. Plasmid
DNA was isolated from these and transformed into E. coli
TG1.
Cell Monolayer Binding Assay—Breast cancer cells were
seeded into 24-well plates and grown to 60–70% confluency
then transfected according to manufacturer’s instructions in
serum-containing medium for 36 h. Sf9 cells were seeded into
24-well plates and infected with virus harboring the IGFBP-
3RFLAG cDNA for 48 h. Cells were washed with cold PBS, then
incubated for 3 h at 12 °C in binding buffer (1Hanks’ buffered
salt solution, 1 mM CaCl2, 1 mM MgCl2, 0.5% BSA) containing
125I-IGFBP-3 (Diagnostic Systems Laboratories) at 50,000 cpm
perwell in triplicatewith orwithout unlabeled IGFBP-3 as indi-
cated in the Fig. 1 legend. The binding solution was then aspi-
rated, and the cells were washed in cold binding buffer (without
BSA), lysed in 0.25 NNaOH, and then the radiolabeled IGFBP-3
was detected in a gamma counter.
Synthesis of siIGFBP-3R—Double-stranded RNAs targeting
IGFBP-3R were purchased from Dharmacon, Inc. We used 4
sets of IGFBP-3R siRNAs consisting of a 21-nucleotide sense
and antisense strand: IGFBP-3R siRNA #1 (sense, 5-GUGAG-
GAAUGUGUUAGUGUUU-3; antisense, 5-ACACUAACA-
CAUUCCUCACUU-3); IGFBP-3R siRNA #2 (sense, 5-GAC-
AACUGGUCCUUAUCACUU-3; (antisense, 5-GUGAUAA-
GGACCAGUUGUCUU-3); IGFBP-3R siRNA #3 (sense, 5-
GGAACAAGACCCGGACAUUUU-3, antisense 5-AAUGU-
CCGGGUCUUGUUCCUU-3); IGFBP-3R siRNA #4 (sense,
5-GGAACCUGCCUAUAUUUUAUU-3; antisense, 5-
UAAAAUAUAGGCAGGUUCCUU-3). siCONTROL Non-
Targeting siRNA #1 (Dharmacon) was used as a nonspecific
control. A mixture of 4 sets of IGFBP-3R siRNAs (total 20 nM)
was transfected for 6 days in M12 prostate cancer cells. Two
target sequences corresponding to siRNAs #1 and #3 were fur-
ther selected to construct shRNA plasmids using pSUPER
RNAi SystemTM (OligoEngine): for pSRN IGFBP-3R shRNA#1
(526 to 544; sense, 5-gatccccGTGAGGAATGTGTTAG-
TGTttcaagagaACACTAACACATTCCTCACttttta-3; anti-
sense, 5-agcttaaaaaGTGAGGAATGTGTTAGTGTtctcttgaa-
ACACTAACACATTCCTCACggg-3); for pSRN IGFBP-3R
shRNA #3 (300 to318; sense, 5-gatccccGGAACAAGACC-
CGGACATTttcaagagaAATGTCCGGGTCTTGTTCCttttta-3;
antisense, 5-agcttaaaaaGGAACAAGACCCGGACATTtct-
cttgaaAATGTCCGGGTCTTGTTCCggg-3). The comple-
mentary sequences was annealed together and inserted into the
BamHI and HindIII site of pSRN, generating pSRN-IGFBP-3R
shRNA #1 or pSRN-IGFBP-3R shRNA #3, respectively.
Generation of Adenoviral IGFBP-3 and IGFBP-3R—Weused
NotI-XbaI restriction fragments from pcDNA3/wild type
IGFBP-3 cDNA and EcoR1-Xho1 restriction fragments from
CS2-IGFBP-3RF to ligate into NotI-XbaI-digested pShuttle-
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CMV and EcoRV-digested pShuttle-CMV, respectively. We
used SalI-NotI restriction fragments from pcDNA3.1/LacZ
(Invitrogen) to ligate into SalI-NotI-digested pShuttle-CMV.
Recombination into the pAdEasy viral backbone was accom-
plished in E. coli strain BJ5183 according to the manufacturer’s
instructions. The recombination was verified, and the adenovi-
ral recombinant DNA was transferred to DH5. We purified
recombinant pAdEasy plasmids containing CMV-cDNA
inserts using Qiagen columns (Qiagen) and transfected QBI-
293A cells with 5 g of PacI-digested DNA using the calcium
phosphate method (Promega). Cells were seeded at 2  106
cells per 150-mm culture dish 24 h before transfection. Lysis of
transfected cells, indicating adenoviral growth, occurredwithin
4 days. After amplification, lysates containing clonal recombi-
nant Ad were prepared from 150-mm culture dishes and puri-
fied by CsCl gradient centrifugation. Recovered virus was sep-
arated into aliquots and stored at20 °C in 5 mM Tris, pH 8.0,
buffer containing 50 mM NaCl, 0.05% bovine serum albumin
(BSA), and 25% glycerol.We performed viral titrate assay using
serial dilution infection ofQBI-293Acells and counting plaques
under an overlay of 0.3% agarose, 10% FBS, and 1 Dulbecco’s
modified Eagle’s medium.
Semiquantitative PCR—One g of purified total RNA was
used for RT-PCR analysis using theThermoScript RT-PCR sys-
tem (Invitrogen). The sequences of the forward and reverse
primers were as follows: IGFBP-3 (forward, 5-GACTC-
TGCTGGTGCTGCTC-3; reverse, 5-GCATGCCCTTTCT-
TGATGAT-3); IGFBP-3R forward (5-ATGGGACAGTCA-
CAGGGAAG-3; reverse, 5-AAGGCCACAGAAGAGAAGCA-
3); 2M forward (5-GTGCTCGCGCTACTCTCTCT-3;
reverse, 5-CGGCAGGCATACTCATCTTT-3). The IGFBP-3
PCR product is 501 bp in length, IGFBP-3R is 437 bp, and 2M
is 278 bp. For PCR amplification, 35 cycles were performed for
IGFBP-3 and IGFBP-3R, and 30 cycles for 2M (denaturation:
95 °C, 1 min; annealing: 60 °C, 1 min; polymerization: 72 °C, 1
min). Amplified products were electrophoresed on a 2.0% aga-
rose gel, andDNAwas visualized by ethidiumbromide staining.
Northern Blotting—We used Human Multi-tissue Northern
Blots I & II (Clontech). Total RNAs frommonolayer cultures of
human breast and prostate cells were harvested using the
RNeasy RNA isolation kit (Qiagen). Five g of total RNA from
each cell linewere run on 1% formaldehyde gels and transferred
ontoGeneScreen Plus nylonmembranes (PerkinElmer Life Sci-
ences). Membranes were UV-cross-linked and stained in 0.02%
methylene blue, 0.3 M NaOAc, pH 5.5. 32P-Labeled cDNA
probes were prepared using the Prime IT II kit (Stratagene).
Membranes were hybridized in Rapid-Hyb buffer (Amersham
Biosciences), washed in 0.3 SSC (1 SSC 0.15 M NaCl and
0.015 M sodium citrate), and exposed to film.
Cell Proliferation Assays—We carried out cell proliferation
assays using the MTT Cell Proliferation Assay (ATCC). Cells
were seeded in triplicate in 96-well microtiter plates, grown to
60–70% confluency, and treated as indicated. MTT was added
to the cell culture and incubated for 4 h at 37 °C. The assays
were performed according to the manufacture’s protocol.
Biotinylation of IGFBP-3—Non-glycosylated E. coli-derived
IGFBP-3 was biotinylated using the p-biotinoyl aminocaproic
acid-N-hydroxy-succinamide ester (Thermo Scientific Pierce)
at room temperature (20). At the end of incubation free biotin
ester was separated on a Sephadex G-25 column (Bio-Rad).
In Vitro Transcription and Translation Techniques (TNT)—
Each linear plasmid DNA template of IGFBP-3R and caspase-8
was translated separately in the presence of wheat germ
extracts, T7b RNA polymerase, and amino acid mixture
according to themanufacturer’s protocol (Promega). Amixture
of the two proteins was co-immunoprecipitated with IGFBP-3R
antibodies, and the resultants were furtherWestern-blotted using
caspase-8 and IGFBP-3R antibodies.
IGFBP-3R Binding Assay—Cos-7 cells were infected with
Ad:IGFBP-3R for 2 days. The cells were lysed in HBSST (HBSS
with 0.035% sodium bicarbonate, 0.5% Triton X-100, 1 mM
MgSO4, and 1 mM CaCl2, pH 7.4) supplemented with HaltTM
Protease Inhibitor (Roche Applied Sciences). A 96-well plate
was coated with 50 l of anti-FLAG antibody diluted in PBS at
10 ng/l per well overnight at 4 °C. Thewells were blockedwith
300 l of HBSST containing 5% BSA (HBSST-BSA) for 1 h at
room temperature. The wells were washed 3 times with 300 l
of PBS containing 0.2% Tween 20. Cell lysates (10 g/50
l/well) were added and incubated for 1 h at room temperature.
After washing, 16 nM biotinylated IGFBP-3 was incubated in
the presence of 0–100 nM IGFBP-3 (Celtrix) for 1 h at room
temperature. The wells were incubated with HRP-conjugated
streptavidin (Thermo Scientific) diluted in 50 l of HBSST-
BSA for 1 h at room temperature and further incubated with 50
l of 3,3,5-5-tetramethyl benzidine substrate (Sigma). The
reaction was terminated by adding 50 l of 1 N H2SO4, and
absorbance was measured at 450 nm.
Immunofluorescence Staining—Weseeded cells in a chamber
slide (Lab-Tek II Chamber Slide System, Nalge Nunc Interna-
tional) and infected cells with Ad:IGFBP-3R for 2 days. Adher-
ent cells were washed with PBS and fixed in 3% paraformalde-
hyde for 10min at room temperature. After washing twice with
PBS, cells were permeabilized with 0.1% Triton X-100 in PBS
for 5 min at room temperature, washed twice with PBS, and
blocked in 1% BSA with 1% normal goat serum in PBS for
30 min at room temperature. We incubated slides with -
IGFBP-3R or -FLAG antibodies at a 1:100 dilution in blocking
buffer for 30 min at room temperature and washed slides twice
with PBS. We incubated slides with secondary goat anti-rabbit
IgG Alexa Fluor 568 or goat anti-mouse IgG fluorescein iso-
thiocyanate at a 1:200 dilution for 45 min followed by 3 washes
with PBS. Next we counterstained the nuclei with Hoechst (1
g/ml) for 5min. Slides were washed three times with PBS, and
stained slides were mounted with VECTASHIELD Mounting
Medium (Vector Laboratories) and analyzed under a confocal
microscope (Leica TCS-SP2 AOBS).
Cell Lysates, Subcellular Fraction Preparations—Cell lysates
were harvested by washing monolayer cultures in ice-cold PBS
then lysing in Triton lysis buffer (20 mM Tris, pH 7.6, 150 mM
NaCl, 1% Triton X-100). Plates were rocked at 4 °C for 15 min,
and lysates were collected and centrifuged to remove cellular
debris. For subcellular fraction preparations, plasma mem-
brane and cytosolic and nuclear fractions were isolated by
homogenizing cells using the membrane protein extraction kit
(Bio Vision) and centrifuging successively at 700 and 100,000
g for 10 and 60 min, respectively. All pellets were solubilized in
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50 mM HEPES, pH 7.4, 150 mM NaCl, 2 mM MgSO4, 1% Triton
X-100. Equal amounts of protein from each fraction were ana-
lyzed by SDS-PAGE followed byWestern blotting for fraction-
ation specific markers.
Immunoprecipitations and Western Blotting—For immuno-
precipitations, cleared cell lysates were diluted in 20 mM Tris,
pH 7.6, 150 mM NaCl and adjusted to a final concentration of
0.5% Triton X-100 (immunoprecipitation buffer). Antibodies
and Protein A or Protein G-Sepharose (Amersham Bio-
sciences) were added, and reactions were incubated at 4 °C for
4 h. Beads were washed twice in immunoprecipitation buffer
and suspended in 1 reducing sample buffer. Sampleswere run
on 12.5% reducing SDS-PAGE and electrotransferred onto
Hybond-ECL nitrocellulose (Amersham Biosciences). Mem-
branes were blocked in 5% nonfat milk, Tris-buffered saline,
0.1% Tween 20 (TBS-T). Primary antibodies were diluted in
blocking solution and incubated on the membranes for 2 h at
room temperature. Membranes were washed in TBS-T then
incubated with HRP-conjugated secondary antibody, diluted
1:3000 for 1 h at room temperature, washed, and detected using
the Renaissance Western blot Chemiluminescence reagents
(PerkinElmer Life Sciences).
Caspase Inhibitor Treatment—We purchased cell-permea-
ble caspase inhibitors from BD Biosciences. We infected
MDA231 cells with Ad:IGFBP-3R or Ad:EV and further treated
with 50 M z-VAD-fmk (pan caspase inhibitor), z-IETD-fmk
(caspase-8 specific inhibitor), or z-FA-fmk (inactive caspase
inhibitor) every 24 h.We performed caspase-3/-7 activity assay
and cell death detection ELISA assay at 48 and 72 h after
infection.
Thymidine Incorporation Assay—Cells were seeded in tripli-
cate into 24-well plates, grown to 60–70% confluency, and
transfected and treated as indicated in the Fig. 4 legend. At 48 h
post-transfection, the medium was replaced with serum-free
medium, and cells were further incubated for 24 h. To eachwell
0.1 Ci of [3H]thymidine was added, and the acid-precipitable
radioactivity in each well was assayed 24 h later.
Caspase-3/-7 and -8 Activity Assays—Cells were subse-
quently cultured in media with 1% FBS and infected with
Ad:IGFBP-3 or Ad:EV for 2 days, and cell lysates were prepared
using CHAPS lysis buffer (50 mM HEPES, pH 7.4, 0.10%
CHAPS, 0.10% Triton X-100, 0.1 mM EDTA, and 1 mM dithio-
threitol) and 12,000  g centrifugation at 4 °C. Caspase-3/-7
and -8 activity was measured using 10l of cell lysates and 10
l of 100 M caspase-3 and -7 substrate (Ac-DEVD-
amidomethylcoumarin (AMC)) or caspase-8 substrate (Ac-
IETD-AMC) in assay buffer (50 mM HEPES, pH 7.4, 100 mM
NaCl, 10% CHAPS, 10% glycerol, 10 mM EDTA, and 5 mM
dithiothreitol). The reaction was measured at 37 °C for 6 h,
and fluorescence was measured in a fluorescence plate
reader (BMG LABTECH).
Cell Death ELISAAssay—Apoptotic cell deathwasmeasured
using the cell death detection ELISA (Roche Applied Sciences)
according to the manufacturer’s instructions. Equivalent cell
populations were measured, and absorbance was measured at
405 nm (reference wavelength, 490 nm).
Intratumoral Delivery of Ad:IGFBP-3R in Vivo—Mouse
experiments were performed under a protocol approved by
the Virginia Commonwealth University Institutional Ani-
mal Care and Use Committee (IACUC). M12 prostate cancer
cells or MDA231 breast cancer cells suspended in 100 l of
sterile PBS were injected into the dorsal flank of 4-week-old
male or female athymic nude mice, respectively. Once tumor
volume reached 75 mm3, mice were injected intratumor-
ally 2 times at day 0 and day 6 with 5  109 plaque-forming
units of Ad:IGFBP-3R or Ad:Lac-Z in 50 l of PBS or 50 l of
PBS alone as a control. Tumor size and volume were meas-
ured every 2 days. We harvested tumor tissues for immuno-
histochemistry of -galactosidase, IGFBP-3R, and CD34 16
days after first injection.
Human Samples—Breast and prostate tumor paraffin blocks
were obtained from the archives of the Division of Surgical
Pathologywith approval from the Institutional ReviewBoard of
VirginiaCommonwealthUniversity. To perform semiquantita-
tive RT-PCR, we obtained frozen-fresh prostate tumor tissues
from the Tissue/Tumor Procurement Facility of the Oregon
Cancer Center with approval from the Institutional Review
Board of Oregon Health Sciences University. Total RNA was
purified from tumor tissues using the TRIZOL (Invitrogen)
extraction technique as recommended by the manufacturer.
One g of purified total RNA was used for RT-PCR analysis
using the ThermoScript RT-PCR System (Invitrogen) and spe-
cific primers.
Immunohistochemistry of Human and Mouse Tissue—Slides
with the human andmouse tissue sections were dried in a 65 °C
oven for 1 h before staining. The tissue sections were deparaf-
finized in xylene and rehydrated in decreasing grades of alcohol
(100, 90, and 80%) and rinsed in PBS. We quenched endoge-
nous peroxidase activity by incubating tissue sections in 3%
hydrogen peroxide for 5 min. The slides are placed in the
steamer for heat target antigen retrieval at the optimal deter-
mined pHof 9.We incubated slideswith the primary antibodies
for IGFBP-3 (1:100 dilution), IGFBP-3R (1:100 dilution), or
CD34 (1:100 dilution) for 1 h at room temperature and then
rinsed twice in Dako wash buffer. We further incubated slides
with appropriate secondary antibody for 30 min then rinsed
and applied a HRP-labeled EnvisionTM polymer. The specific
antibody and conjugated polymer enzyme complex was visual-
ized using the EnvisionTM Dual Link System-HRP (DAB)
system after thorough washing. We counterstained tissue sec-
tions with Gill’s III hematoxylin for 30 s.
Statistical Analyses—We conducted statistical analysis by
analysis of variance with Student’s t test. We considered a p
value of 0.05 or less as significantly different.
RESULTS
Identification of a Novel IGFBP-3R and Its Endogenous Ex-
pression on Cell Membrane—The yeast two-hybrid screening
was performed to identify a potential IGFBP-3 receptor using a
cDNA construct encoding the mid region (amino acids
88–148) of the IGFBP-3 protein as bait against an Hs578T,
human breast cancer cell cDNA library. This screen resulted in
the identification of a cDNA, later designated IGFBP-3R, rep-
resenting a novel gene composed of 915 base pairs and encod-
ing a 240-amino acid polypeptide (GenBankTM accession
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#FJ748884). Genomic data base analysis identified 4 exons
composing the cDNA sequence on chromosome 16q13.
Northern blot analysis indicated a wide distribution of
IGFBP-3R mRNA in human tissues. The 0.9-kb mRNA was
detected to varying degrees in normal human tissues (Fig. 1A).
A second roughly 2-kb transcript was detected in testis, the
significance of which, if any, is not known. The deduced amino
acid sequence indicates that IGFBP-3R consists of an N-termi-
nal putative signal peptide sequence, three potential N-glyco-
sylation sites, a putative single-span transmembrane domain,
and a short C-terminal cytoplasmic domain (Fig. 1B). Interest-
ingly, its transmembrane domain contains a leucine zipper-like
heptad repeat pattern of amino acids similar to the single-span
transmembrane leucine zipper sequences identified in erythro-
poietin receptor and discoidin domain receptor (Fig. 1B, inset,
and Refs. 21 and 22).
To examine the endogenous protein, a rabbit polyclonal anti-
bodywas generated againstGST-fused IGFBP-3Rpurified from
E. coli. The IGFBP-3R antibody recognized a species of roughly
32 kDa from human breast cancer cell lysates (Fig. 1B, right
panel). We further examined whether IGFBP-3R is a cell mem-
brane protein and whether IGFBP-3 interacts with IGFBP-3R
on the cell surface using monolayer binding assays with 125I-
labeled IGFBP-3, cell fractionation preparations by differential
centrifugation, and confocal microscopy. Overexpression of
IGFBP-3R resulted in a 1.5- and 3.5-fold increase in IGFBP-3
cell surface binding to MCF-7 and Sf9 cell monolayers relative
to cells expressing endogenous levels of IGFBP-3R, respectively
(Fig. 1C, left panel). Total binding was competed in a dose-de-
pendent manner with the addition of unlabeled IGFBP-3, dem-
onstrating IGFBP-3R specificity for binding IGFBP-3. The
presence of the FLAG tag at the C terminus of the IGFBP-3R
protein had no effect on IGFBP-3 binding (Fig. 1C, right panel).
In addition, the IGFBP-3R antibody recognized a species of
roughly 32 kDa in plasmamembrane and cytoplasmic fractions
but not in nuclear fraction in human breast cancer cells (Fig.
1D). In accordance with these findings, confocal microscopy
confirms that both endogenously produced and overexpressed
IGFBP-3R exists on the cell membrane of human breast cancer
cells (Fig. 1D).
Specific Interaction of IGFBP-3R with IGFBP-3—To charac-
terize the specific interaction between IGFBP-3 and IGFBP-
3R in a mammalian system, coimmunoprecipitation and
IGFBP-3R binding assays were performed. A coimmunopre-
cipitation experiment was initially carried out using the EGFP:
IGFBP-3R fusion protein and FLAG-tagged IGFBP-3 produced
in a baculovirus system. A specific interaction of IGFBP-3 and
IGFBP-3Rwas observed (Fig. 2A). Similar results were obtained
using MDA231 cells infected with adenoviral constructs con-
taining the FLAG-tagged IGFBP-3R cDNA sequence. When
cell lysates from Ad:EV- or Ad:IGFBP-3RF-infected cells were
immunoprecipitated with FLAG M2 antibodies and proteins
were detected on Western immunoblots with IGFBP-3R anti-
bodies. Both endogenous IGFBP-3R and overexpressed IGFBP-
3RF were detected in both cell lysates, whereas FLAG-tagged
IGFBP-3R was detected in cell lysates from Ad:IGFBP-3RF-in-
fected cells after immunoprecipitationwith FLAGM2 antibod-
ies (Fig. 2B). When the FLAG antibody was used for immuno-
precipitation, recombinant IGFBP-3 was precipitated with
IGFBP-3RF (Fig. 2, C and D). Specificity of coimmunoprecipi-
tation was demonstrated by showing that IGFBP-3 is only
coprecipitated with the Ad:IGFBP-3RF-infected cell lysates but
not with the Ad:EV-infected cell lysates (Fig. 2D). To further
demonstrate the interaction between endogenously expressed
IGFBP-3 and IGFBP-3R, MDA231-conditioned media was
immunoprecipitated with IGFBP-3R antibodies in the pres-
ence/absence ofMCF-7 cell lysates. As shown in Fig. 2E, endog-
enous IGFBP-3 in MDA231-conditioned media was coprecipi-
tated with endogenously produced IGFBP-3R in MCF-7 cells
when IGFBP-3R antibodies were used for immunoprecipita-
tion. Additional coimmunoprecipitation assays with IGFBPs
1–6 reveal that the interaction of IGFBP-3 and IGFBP-3R
was evident, but no interactionwas detectedwith other IGFBPs
(Fig. 2F). Furthermore, the IGF-I and IGFBP-3 complex was
unable to bind IGFBP-3R, indicating that binding of IGFBP-3 to
IGF and IGFBP-3R is mutually exclusive (Fig. 2D), and IGF-I
may regulate the IGFBP-3/IGFBP-3R-induced biological func-
tion by preventing IGFBP-3 binding to IGFBP-3R (10). In vitro
IGFBP-3R binding assays were further performed using biotin-
labeled IGFBP-3 and purified IGFBP-3R. The interaction
between IGFBP-3 and IGFBP-3R was specific and saturable
(Fig. 2G, left panel). A competitive binding assay revealed a
dose-dependent competition with unlabeled IGFBP-3 with
IC50  0.5 nM but not with unlabeled IGFBP-5 (Fig. 2G, right
panel).
Significance of IGFBP-3/IGFBP-3R in Human Cancer—To
assess the significance of the IGFBP-3/IGFBP-3R axis in tu-
morigenesis, the distribution of IGFBP-3 and IGFBP-3R was
examined in normal and malignant human breast and prostate
specimens. Although IGFBP-3 and IGFBP-3R were readily
detected in benign breast lobule and benign prostate tissues,
heterogeneous but significantly reduced expression of IGFBP-3
and IGFBP-3R was observed in invasive breast ductal carci-
noma and prostate adenocarcinoma cells (Fig. 3A). Heteroge-
neous but significantly reduced mRNA expression of IGFBP-3
and IGFBP-3R were also observed in prostate tissue (Fig. 3B).
These data indicate that the IGFBP-3/IGFBP-3R axis is
impaired during the progression of breast and prostate tumor,
and restoration of the IGFBP-3/IGFBP-3R axis might play a
role in suppression of tumor growth.
The role of IGFBP-3R in prostate and breast tumor in vivo
was further examined with an athymic nude mouse model
using M12 human prostate cancer cells and MDA231 breast
cancer cells. Initial tests revealed that the adenoviral titer, 5 
109 plaque-forming units, was optimal in terms of in vivo
expression efficiency and cytotoxic effect on M12 prostate
tumor in the nude mice (Fig. 3C). Intratumoral injection of
Ad:IGFBP-3RF intoM12 cell tumors in nude mice resulted in a
significant shrinkage of tumor mass without any obvious toxic
effect on mice 16 days after viral injection. Compared with
Ad:Lac-Z-infected tumor, Ad:IGFBP-3R tumor showed a 40%
reduction in tumor mass (Fig. 3D). A similar anti-tumor
effect of IGFBP-3R was obtained in a MDA231 breast tumor
nude mouse model (43% reduction in tumor mass). Immu-
nohistochemistry with CD34 antibody revealed that IGFBP-
3R-overexpressed tumor also exhibit significant suppression
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FIGURE 1. IGFBP-3-interacting protein, IGFBP-3R, is a single-span membrane protein and widely expressed in human normal tissue but sup-
pressed in prostate and breast tumor. A, Northern blot analysis of IGFBP-3R mRNA expression is shown. Multiple human tissue Northern blots I and
II (Clontech) were probed with 32P-labeled IGFBP-3R cDNA. B, left panel, shown is a schematic diagram of IGFBP-3R sequences demonstrating an
N-terminal putative signal peptide sequence, three potential N-glycosylation sites, a putative single-span transmembrane domain with a leucine
zipper-like heptad repeat sequence, and a short C-terminal cytoplasmic domain. Inset, shown is the alignment of the putative transmembrane segment
in IGFBP-3R with the heptad repeat pattern characteristic of leucine zipper interaction domains identified in erythropoietin receptor and discoidin
domain receptor. The letters in bold correspond to a- and d-type interfacial residues in leucine zipper interaction domains. Right panel, detection of
endogenous IGFBP-3R and adenoviral transduced IGFBP-3RF by immunoblotting is shown. The IGFBP-3R antibody recognized a 32-kDa species from
MDA231 breast cancer cell lysates. C, IGFBP-3-IGFBP-3R interaction on cell surface is shown. Monolayer affinity binding data showed a significant
increase in radiolabeled IGFBP-3 cell surface binding on cells overexpressing IGFBP-3R compared with control-transfected cells (left panel). Competitive
inhibition of IGFBP-3 cell surface binding with unlabeled IGFBP-3 in MCF-7 cells is shown (right panel). The presence of the FLAG-tag at the C terminus
of the IGFBP-3R sequence had no effect. Error bars show S.D. n  3 in duplicate. *, p  0.1; **, p  0.05. D, subcellular localization of IGFBP-3R by cell
fractionation and confocal microscopy is shown. Left panel, endogenous IGFBP-3 was detected in plasma membrane and cytoplasmic fractions in
human breast cancer cells. Subcellular fractionswere prepared by differential centrifugation. 100g of proteinswere subjected toWestern immunoblot
with -IGFBP-3R antibodies. 3 integrin, -tubulin, and histone deacetylase (HDAC) were used as plasmamembrane (Memb), cytosol (Cyto), and nuclear
(Nuc) markers, respectively. Right panel, both endogenous and overexpressed IGFBP-3R is readily detectable on the cell membrane as well as in
perinuclear and cytoplasmic area using IGFBP-3R and FLAG M2 antibodies. Hoechst stain (blue) was used to identify nuclei.
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of tumor angiogenesis (Fig. 3C). These findings indicate that
overexpression of IGFBP-3R may enhance paracrine/auto-
crine-derived IGFBP-3-induced tumor suppression, and thus,
IGFBP-3/IGFBP-3R axis represents
a novel signaling pathway that
inhibits tumor growth.
IGFBP-3R Mediates IGFBP-3-
induced Growth Inhibition and
Apoptosis—To determine whether
IGFBP-3R mediates antiprolifera-
tive effect of IGFBP-3, the growth
inhibitory actions of endogenous
IGFBP-3 via IGFBP-3R were ini-
tially tested using IGFBP-3-express-
ing Hs578T and MDA231 human
breast cancer cells, PC-3 prostate
cancer cells, and NCI-H157 non-
small cell lung carcinoma cells. Sig-
nificant cell growth inhibition was
observed in Ad:IGFBP-3R-infected
in a m.o.i.-dependent manner but
not Ad:EGFP-infected Hs578T cells
(Fig. 4A). IGFBP-3R overexpression
resulted in growth inhibition up to
90% in IGFBP-3-expressing cancer
cells, whereas adenoviral vector
itself shows no growth inhibition
(Table 1). It was further tested
whether IGFBP-3R-induced growth
inhibition results from induction
of apoptosis. Treatment with the
pan-caspase inhibitor z-VAD-fmk
resulted in a complete abrogation of
both etoposide- and IGFBP-3R-in-
duced cell growth inhibition in
Hs578T cells, suggesting that the
IGFBP-3R might play a role in
IGFBP-3-induced apoptosis (Fig.
4B). Furthermore, IGFBP-3R over-
expression effectively increases
caspase-3/-7 activities in IGFBP-3-
expressing cancer cells, reaching
maximum activity 48 h after infec-
tion (p  0.01 in Hs578T and
MDA231 cells and p 0.05 in PC-3
and H157 cells). This suggests that
IGFBP-3R mediates endogenous
IGFBP-3-induced growth inhibi-
tion via activation of caspase-
dependent cell death signaling
(Fig. 4C).
To investigate whether IGFBP-3R
is required for the growth inhibitory
action of IGFBP-3, IGFBP-3-nonex-
pressing MCF-7, inducible stably
transfected MCF-7:IGFBP-3 sub-
line (MCF-7:IGFBP-3 clone #3
(Ref. 19)), and IGFBP-3-expressing
MDA231 breast cancer cells were employed (Fig. 3D). Induc-
tion of IGFBP-3 expression by 15 M ponasterone A treatment
in MCF-7:IGFBP-3 #3 cells resulted in an inhibition of DNA
FIGURE 2. Specific interaction between IGFBP-3 and IGFBP-3R. A, coimmunoprecipitation of IGFBP-3F and
IGFBP-3R fused to EGFP is shown. Cell lysates from transfected cells were immunoprecipitated (IP) with either
FLAGM2 or GFP antibodies, and immunoprecipitated proteins were detected onWestern immunoblots (WIB)
with the opposing antibody. B, detection of endogenous and overexpressed FLAG-tagged IGFBP-3R by
IGFBP-3R antibodies is shown. Both endogenous IGFBP-3R and overexpressed IGFBP-3RF were detected in
both cell lysates, whereas FLAG-tagged IGFBP-3Rwas detected in cell lysates fromAd:IGFBP-3RF-infected cells
after immunoprecipitation with FLAG M2 antibodies. C, coimmunoprecipitation of recombinant IGFBP-3 and
IGFBP-3RF is shown. Cos-7 cell lysates from Ad:IGFBP-3RF-infected cells were immunoprecipitated with FLAG
M2antibodies, and immunoprecipitatedproteinsweredetectedonWestern immunoblotswith either IGFBP-3
or IGFBP-3R antibodies.D, coimmunoprecipitation of recombinant IGFBP-3 and IGFBP-3R is shown. Cell lysates
from Ad:EV- or Ad:IGFBP-3RF-infected cells were immunoprecipitated with FLAG M2 antibodies in the pres-
ence/absence of IGFBP-3. Immunoprecipitated proteins were detected by Western immunoblots with
-IGFBP-3 antibodies. E, shown is coimmunoprecipitation of endogenous IGFBP-3 and IGFBP-3R using
MDA231-conditioned media (CM) and MCF-7 cell lysates as the source of endogenous IGFBP-3 and IGFBP-3R,
respectively. Sampleswere immunoprecipitatedwithpolyclonal-IGFBP-3R antibodies and subjected toWestern
immunoblotting using polyclonal -IGFBP-3 or -IGFBP-3 antibodies. 40–45-kDa glycosylated endogenous
IGFBP-3wasprecipitatedwithendogenouslyproduced IGFBP-3R (sixth lane),whereas IGFBP-3 isundetectable in its
immunoprecipitation supernatants (Sup, fourth lane). Endogenous IGFBP-3R was precipitated by -IGFBP-3R anti-
bodies (sixth lane). In contrast, when IGFBP-3-containing conditioned media was immunoprecipitated in the
absenceof IGFBP-3R-containing lysates, the IGFBP-3bandwasdetectedonly in immunoprecipitation supernatants
(third lane) but not in the immunoprecipitated samples (fifth lane). F, representative results of coimmunoprecipita-
tionandWestern ligandblottingwith IGFBP-3Rand IGFBPs1–6are shown.5nM IGFBPsor incombinationwith5nM
IGF-I was incubated with cell lysates from IGFBP-3RF-overexpressed cells and immunoprecipitated with -FLAG
antibodies. Immunoprecipitated IGFBPs were detected by I125-IGF-I/-II ligand blotting. The interaction of IGFBP-3
and IGFBP-3Rwasevident,butno interactionwasdetectedwithother IGFBPs.G, left panel, abindingassaybetween
biotinylated IGFBP-3 and IGFBP-3R is shown. Right panel, competitive binding of biotinylated IGFBP-3 to IGFBP-3R
was assessed in the presence of increasing amounts of unlabeled IGFBP-3 (closed circle) or IGFBP-5 (closed square).
Error bars represent S.D. n 3 in duplicate.
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synthesis by an average of 45% compared with controls in
MCF-7 cells (Fig. 4D, left panel). With additional overexpres-
sion of IGFBP-3R in these cells, DNA synthesis was further
inhibited by an average of 65%. Overexpression of IGFBP-3R
had no significant effect on DNA synthesis in the absence of
IGFBP-3 (either wild type MCF-7 or uninduced MCF-7:
IGFBP-3 #3 cells). In IGFBP-3-expressingMDA231 cells, over-
expression of IGFBP-3R resulted in a 2.5-fold increase of the
cell death compared with controls measured by cell death
ELISA assays (Fig. 4D, right panel).When endogenous IGFBP-3
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was suppressed by treatment of IGFBP-3 shRNA (23) in these
cells, IGFBP-3R overexpression-induced cell death was signifi-
cantly inhibited (2.5- versus 1.6-fold, p 0.05). Suppression of
endogenous IGFBP-3without IGFBP-3R overexpression shows
a slight increase of the cell death up to 1.3-fold.
It was further examined whether IGFBP-3R is required for
IGFBP-3-induced apoptosis using IGFBP-3R RNAi tech-
niques in non-IGFBP-3-expressing M12 prostate cancer
cells. After verifying a significant knockdown of endogenous
IGFBP-3R by IGFBP-3R siRNAs at the mRNA and protein
levels, IGFBP-3-induced caspase activity was measured.
Although overexpression of IGFBP-3 resulted in a 500%
increase of caspase activity, specific knockdown of
IGFBP-3R completely inhibited IGFBP-3-induced caspase
activities (Fig. 4E, top panel). No inhibitory effect of
IGFBP-3R siRNA on caspase activities was observed in con-
trol cells or control adenoviral vector-infected cells. Two
target sequences corresponding to siRNAs #1 and #3 were
further selected to construct shRNA plasmids. As shown in
Fig. 4E, bottom panel, transfection of two IGFBP-3R shRNAs
resulted in complete inhibition of IGFBP-3-induced apopto-
sis with concomitant suppression of endogenous IGFBP-3R
expression in M12 cells. These results indicate that IGFBP-3
induces caspase-dependent apoptosis through IGFBP-3R.
IGFBP-3/IGFBP-3R Activates Caspase-8-dependent Cell
Death Signaling—To explore the mechanisms by which the
IGFBP-3/IGFBP-3R axis induces apoptosis, the hypothesis
was tested that IGFBP-3R might be a novel cell death recep-
tor and activate initiator caspases such as caspase-8 and -10
and the subsequent downstream caspases such as caspase-3
and -7. Because IGFBP-3 has been reported to activate
caspase-8 but not caspase-10 in breast cancer cells (19), it
was tested whether IGFBP-3R attributes to activation of
caspase-8 in IGFBP-3-expressing MDA231 breast cancer
cells. IGFBP-3R overexpression resulted in activation of
caspase-8 and -3 in a time-dependent manner, as shown by a
decrease of procaspase-8 and -3 and concomitant appear-
ance of cleaved active forms of both caspases at 36 h after
viral infection (Fig. 5A). Co-treatment with pan-caspase
inhibitor z-VAD-fmk completely prevented the IGFBP-3R-
induced caspase-8 and caspase-3/-7 activities and apoptosis
(Fig. 5B). At the same time, the caspase-8 specific inhibitor
z-IETD-fmk completely abolished the changes in not only
caspase-8 but also caspase-3/-7 activities and apoptotic
index. We further tested the specific role of caspase-8 in the
IGFBP-3/IGFBP-3R axis-induced apoptosis using caspase-8
shRNAs (24). Caspase-8 shRNA treatment resulted in more
than 80% suppression of endogenous caspase-8 expression
and inhibited IGFBP-3/IGFBP-3R-induced apoptosis up to
60% (Fig. 5C). These data clearly demonstrate that caspase-8
is a key initiator caspase involved in the induction of apopto-
sis by the IGFBP-3/IGFBP-3R axis.
Specific Interaction between IGFBP-3R and Caspase-8—
Because IGFBP-3R contains no death domain (DD)
sequence, which is a critical sequence to recruit adapter pro-
teins such as FADD and caspase-8 to the activated death
receptors, the underlying mechanisms for IGFBP-3R-in-
duced activation of caspase-8 were further investigated. Co-
immunoprecipitation studies using IGFBP-3R-overex-
pressed Cos-7 cell lysates clearly demonstrated that
IGFBP-3R binds to caspase-8 without FADD (Fig. 5D, left
panel, third lane). Further coimmunoprecipitation experi-
ments were performed to verify interaction between endog-
enous IGFBP-3R and caspase-8 using Cos-7 cells that pro-
duce both proteins. Endogenous caspase-8 but not FADD
was co-precipitated with endogenously produced IGFBP-3R
in Cos-7 cells when IGFBP-3R antibodies were used for
immunoprecipitation (Fig. 5D, right panel, fourth lane),
whereas neither caspase-8 nor FADD was detected in the
immunoprecipitated samples in the absence of -IGFBP-3R
antibodies (fifth lane). Because recent studies demonstrated
that membrane proteins containing no DD directly interact
with caspase-8 and induce apoptosis (25, 26), the direct
binding of IGFBP-3R to caspase-8 was investigated using a
eukaryotic in vitro TNT. IGFBP-3R and caspase-8 were suc-
cessfully produced by TNT and were comparable with
endogenous proteins expressed in human breast cancer
cells. When TNT-derived IGFBP-3R and caspase-8 were
incubated and immunoprecipitated with IGFBP-3R antibod-
ies, caspase-8 was coprecipitated with IGFBP-3R (Fig. 5E).
These data collectively suggest that IGFBP-3R exists as a com-
plex with caspase-8 at the resting stage and IGFBP-3 binding to
IGFBP-3R activates procaspase-8 and release from the IGFBP-
3R, subsequently activating executioner caspases such as
caspase-3 and -7, thereby inducing apoptosis.
DISCUSSION
The IGF/IGF-IR-independent actions of IGFBP-3 have
been shown to contribute to the pathophysiology of a variety
of human diseases such as cancer, diabetes, ischemia, and
Alzheimer disease (10–14, 27–31). There has been intensive
investigation toward characterizing molecular and cellular
FIGURE 3. Significance of the IGFBP-3/IGFBP-3R axis in human cancer. A, shown are representative immunohistochemistry results of IGFBP-3 and
IGFBP-3R in human breast and prostate tissues. Intense brown staining of IGFBP-3 and IGFBP-3R is readily detectable in benign breast and prostate
epithelial cells as well as stromal fibroblasts. Both IGFBP-3 and IGFBP-3R were significantly reduced in invasive breast ductal carcinoma (IDC) and
prostate tumor cells. No detectable staining was observed with IgG-purified preimmune serum. Original magnification, 200. B, the expression of
IGFBP-3 and IGFBP-3R in normal and malignant prostate specimens was analyzed by semiquantitative RT-PCR. Results were normalized to 2-micro-
globulin (2M). C, the in vivo anti-tumor effect of IGFBP-3R is shown. M12 prostate cancer cells were injected into the dorsal flank of athymic nude mice.
Once tumor volume reached75 mm3, 5 109 plaque-forming units of Ad:IGFBP-3RF or Ad:Lac-Z in 50 l of PBS or 50 l of PBS alone as a control were
intratumorally injected. Representative immunohistochemistry results of M12 cell tumor sample 10-day post-second infection are shown. Intense
brown staining of -galactosidase (-gal) and IGFBP-3RF were detected in Ad:LacZ- and Ad:IGFBP-3R-infected tumors, respectively. CD34 staining was
significantly reduced in Ad:IGFBP-3R-infected tumors. Original magnification, 400. D, decreased size of M12 prostate tumors after adenovirus-
mediated IGFBP-3R over-expression is shown. Tumor size and volume were measured every 2 days for 16 days after injection. Results were expressed as
the mean (S.D.) tumor volume (n 3 for each group) relative to the tumor volume at the time of adenovirus injection (day 0). *, p 0.01 (compared
with control Ad:Lac-Z infection). Similar results were obtained from MDA231 breast tumor bearing athymic nude mice (n  3 for each group).
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mechanisms for IGF/IGF-IR-independent anti-tumor
effects of IGFBP-3 in human cancer in vitro and in vivo.
IGFBP-3 appears to exert its IGF/IGF-IR-independent bio-
logical actions through interaction with a variety of binding
partners on the cell surface and within cells. IGFBP-3 binds
to the low density lipoprotein receptor-related protein-1/
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2M receptor (15), autocrine motility factor/phosphoglu-
cose isomerase (32), caveolin, and transferrin/transferrin
receptor (33, 34) on the cancer cell surface. Functional sig-
nificance of these binding partners on the IGF/IGF-IR-inde-
pendent actions of IGFBP-3 is largely unknown, although
some studies suggested that these interactions may mediate
antiproliferative effects of IGFBP-3 or may result in IGFBP-3
internalization and subsequent biological actions in cyto-
plasmic and nuclear compartments. In addition, IGFBP-3 is
also shown to inhibit cell growth and induce apoptosis
through interaction with nuclear proteins such as retinoid X
receptor (RXR)-, retinoic acid receptor (RAR), and Nur77
(35). IGFBP-3 binds RXR- and RAR and subsequently mod-
ulates RAR/RXR and RXR/Nur77 signaling, thereby induc-
ing apoptosis (36, 37). However, recent studies also showed
that IGFBP-3 mutants that failed to translocate to the
nucleus and lost binding ability to RXR- still induced apo-
ptosis in breast cancer cells (38, 39). Current findings suggest
that IGFBP-3 may utilize multiple mechanisms for its anti-
tumor actions depending upon the cellular environment, or
a major key IGFBP-3 signaling pathway is not yet identified.
This is the first report of an authentic IGFBP-3 receptor that
interacts and functions cooperatively with IGFBP-3 in its IGF/
IGF-IR-independent antiproliferative and proapoptotic func-
tions in cancer cells. Current findings provide evidence for
IGFBP-3R as a cell surface receptor for IGFBP-3, including sub-
cellular localization of IGFBP-3R using cell surface binding, cell
fractionation, and confocal microscopy, specific interaction of
IGFBP-3 with IGFBP-3R on the cell surface, and indispensabil-
ity of IGFBP-3R for IGFBP-3-induced antiproliferative and
proapoptotic functions in cancer cells. Apoptosis can be trig-
gered by internal signals (the intrinsic or mitochondrial path-
way) or external signals (the extrinsic or death receptor path-
way) (40, 41). The initiator caspase in the mitochondrial
pathway is caspase-9, which subsequently activates the execu-
tioner caspases -3, -6, and -7. In contrast, the initiator caspase of
the death receptor pathway is caspase-8. Caspase-8 (like
caspase-9) further activates the cascade of executioner caspases
(-3, -6, and -7). Recent studies reported that the growth inhib-
itory effect of IGFBP-3 results mainly from its induction of
apoptosis via activation of caspases-8 and -7 without release of
cytochrome c into the cytosol and caspase-9 activation in breast
cancer cells, suggesting that IGFBP-3 induces apoptosis
through the activation of caspases via a death receptor-medi-
ated pathway (19). Hence, IGFBP-3R could be responsible for
IGFBP-3-induced activation of the death receptor-mediated
pathway. It is noted that IGFBP-3 has also been shown to
induce themitochondria-mediated apoptosis by suppression of
antiapoptotic proteins Bcl-2 andBcl-XL (42) or interactionwith
RXR- and Nur77 (35–37). However, our IGFBP-3R siRNA
data clearly demonstrate that IGFBP-3R is required for IGFBP-
3-induced caspase-3/-7 activity, and the preceding activation of
caspase-8 is indispensable for IGFBP-3-induced apoptosis in
our cell systems.
IGFBP-3R possesses very unique characteristics; its puta-
tive transmembrane domain contains a leucine zipper-like
heptad repeat pattern of amino acids. Only a few proteins
such as erythropoietin receptor and discoidin domain recep-
tor are known to possess transmembrane leucine zipper
sequences, which may involve dimerization/oligomerization
of membrane proteins (21, 22). Interestingly, the transmem-
brane leucine zipper sequences of IGFBP-3R are similar to
those in erythropoietin receptor; in particular, Ser203,
Leu206, Ser210, and Leu213 in IGFBP-3R are identical to
Ser231, Leu234, Ser238, and Leu241 that occupy a and d posi-
tions of an (abcdefg)n heptad repeat motif in transmembrane
leucine zipper sequences in erythropoietin receptor (Fig. 1B,
FIGURE 4. IGFBP-3Rmediates IGFBP-3-induced growth inhibition and apoptosis. A, growth inhibition by adenoviral-transduced IGFBP-3R is shown.
Efficiency of adenoviral infection was visualized under fluorescence microscopy using Ad:EGFP ranging form an m.o.i. of 100 to 1000 in IGFBP-3-
expressing Hs578T human breast cancer cells (right panel). Significant cell growth inhibition was observed in Ad:IGFBP-3R-infected but not Ad:EGFP-
infected IGFBP-3-expressing Hs578T cells after 48 h of infection (left panel). B, overexpression of IGFBP-3R in Hs578T human breast cancer cells caused
significant growth inhibition, but co-treatment with pan-caspase inhibitor z-VAD-fmk abrogated IGFBP-3R-induced growth inhibition. Etoposide was
used as a positive control for induction of apoptosis. C, overexpression of IGFBP-3R in IGFBP-3-expressing human cancer cells resulted in a significant
increase of apoptosis, as measured by a caspase-3/-7 activity assay. f, Ad:LacZ; Œ; Ad:IGFBP-3R. Error bars represent S.D. n  3 in triplicate. *, p 
0.05; **, p  0.001. D, shown is a demonstration of the requirement of IGFBP-3R for IGFBP-3-induced biological functions in IGFBP-3-nonexpressing
MCF-7 (left panel) and IGFBP-3-expressing MDA231 cells (right panel). Left panel, MCF-7 and MCF-7:IGFBP-3 #3 cells were infected with Ad:IGFBP-3R
(closed) or Ad:EV (open) with/without 15 M ponasterone A treatment and subjected to a [3H]thymidine incorporation assay. Right panel, IGFBP-3-
expressingMDA231 cells were infectedwith Ad:IGFBP-3R in the presence or absence of IGFBP-3 shRNA retrovirus. The cells were harvested on day 5, and
apoptotic cell death was measured by the quantitative detection of histone-associated DNA fragments using the cell death detection ELISA assays.
IGFBP-3R overexpression resulted in induction of cell death, but its effects were inhibited by cotreatment with IGFBP-3 shRNA. Error bars show S.D. n
3 in triplicate; *, p  0.05. The pSRN-IGFBP-3 shRNA inhibited endogenous IGFBP-3 expression. Conditioned media were collected and subjected to
western immunoblots with -IGFBP-3 antibodies (insert). E, shown is suppression of IGFBP-3-induced caspase activity (top panel) and apoptosis (bottom
panel) by IGFBP-3R siRNAs and shRNAs, respectively. Top panel, 20 nM IGFBP-3R siRNAswere transfected for 6 days inM12 prostate cancer cells. Total RNA
and cell lysates were collected and subjected to RT-PCR and Western immunoblots (WIB), respectively (inset). M12 cells were infected with Ad:IGFBP-3
(m.o.i. 250) or Ad:EV (m.o.i. 250) in the presence of IGFBP-3R or nonspecific control siRNAs. Cell lysates were collected and subjected to a caspase-3/-7
activity assay. Five M etoposide was used as a positive control for induction of caspase activity. Error bars show S.D. n 3 in duplicate. *, p 0.05; **,
p  0.001. Bottom panel, M12 cells were transfected with pSRN, pSRN-IGFBP-3R shRNA #1, or pSRN-IGFBP-3R shRNA #3 using Lipofectamine 2000
(Invitrogen) on Day 2 and Day 4 in the presence of 10% FBS. The cells were infected with Ad:IGFBP-3 (m.o.i. 100) or Ad:EV (m.o.i. 100) in the presence of
1% FBS on day 5. The cells were harvested on day 7 and subjected to cell death ELISA assays. Some cells were treated twice with 50 M pan-caspase
inhibitors (z-VAD-fmk) on days 5 and 6. Cell lysates were subjected to Western immunoblots (inset).
TABLE 1
Anti-proliferative effects of IGFBP-3R
IGFBP-3-expressing human cancer cells were infected with Ad:IGFBP-3R or Ad:EV
with and an m.o.i. 500 for Hs578T and an m.o.i. 250 for other cancer cells. MTT
assaywas performed after 3 days of infection.Error bars showS.D.n 3 in triplicate.
Cell lines A492 reading Cell growthControl IGFBP-3R
Arbitrary units % of control
Hs578T 1.86 0.16 0.79 0.13 42 2.0a
MDA231 0.38 0.18 0.08 0.05 21 4.0a
PC-3 0.62 0.13 0.06 0.06 10 2.9a
NCI-H157 1.82 0.38 0.53 0.19 29 3.0a
ap 0.001.
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FIGURE 5. Potential mechanism of IGFBP-3/IGFBP-3R-induced caspase-dependent apoptosis. A, overexpression of IGFBP-3R in IGFBP-3-expressing
MDA231 breast cancer cells resulted in activation of caspase-8 and -3 in a time-dependent manner. MDA231 cells were infected with Ad:IGFBP-3R or
Ad:EV, and inactive and cleaved active forms of caspase-3 and -8 were detected by immunoblotting. B, overexpression of IGFBP-3R in IGFBP-3-
expressing MDA231 breast cancer cells resulted in activation of caspase-3/-7 and -8 activities (left panel) and apoptosis (right panel). IGFBP-3R effects
were abolished by cotreatment with pan-caspase and caspase-8 inhibitors (z-VAD-fmk and z-IETD-fmk) but not by inactive caspase inhibitor (z-FA-fmk).
Error bars show S.D. n  3 in duplicate. C, infection of Ad:caspase-8 shRNA inhibited endogenous caspase-8 expression in a m.o.i.-dependent manner
(inset), and Ad:caspase-8 shRNA (m.o.i. 5) abolished IGFBP-3-induced apoptosis in non-IGFBP-3-expressing T47D breast cancer cells. Error bars show S.D.
n  3 in duplicate. Cont, control. D, IGFBP-3R pulled down caspase-8 but not FADD. Left panel, IGFBP-3R-overexpressed Cos-7 cell lysates were
coimmunoprecipitated (IP) with FLAG M2-agarose beads and immunoblotted for IGFBP-3R, caspase-8, and FADD. Right panel, coimmunoprecipitation
of endogenous IGFBP-3R and caspase-8 is shown. Sup, supernatant. Cos-7 cell lysates were immunoprecipitated with polyclonal -IGFBP-3R antibodies
or protein A/G beads alone and subjected to Western immunoblotting using polyclonal -IGFBP-3R or monoclonal -caspase-8 or -FADD antibodies.
Endogenous caspase-8 but not FADD was co-precipitated with endogenously produced IGFBP-3R when -IGFBP-3R antibodies were used for immu-
noprecipitation (lane 4). E, a direct binding between IGFBP-3R and caspase-8 is shown. IGFBP-3R (third lane 3) and caspase-8 (fourth lane) produced by
the in vitro TNT were comparable with endogenous proteins expressed in MDA-231 and Hs578T breast cancer cells. Coimmunoprecipitation of the
mixed samples with -IGFBP-3R antibodies resulted in pulldown of caspase-8 with IGFBP-3R (lane 5). WIB, Western immunoblot.
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inset). Recent studies demonstrated that those sequences are
critical to form the dimer/oligomers in erythropoietin recep-
tor (21). Further structure-function analysis using specific
mutants would warrant the significance of the transmem-
brane leucine zipper sequences on the activity and signaling
pathway of the IGFBP-3R. Additionally, IGFBP-3R interacts
with initiator caspase-8 without a DD sequence in the intra-
cellular portion of the receptor unlike other known death
receptors such as tumor necrosis factor- (TNF-) receptor,
TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-
R1/DR4), TRAIL-R2 (APO-2/DR5), and CD95 (Fas, APO-1).
Although the DD sequence is critical in forming death-in-
ducing signaling complex (DISC) by recruiting adaptor pro-
teins (FADD) and initiator caspases (caspase-8) after recep-
tor activation, recent studies demonstrated that clusters of
unligated integrins containing no DD directly interact with
caspase-8 and induce apoptosis (26). In addition, a novel
600-kDa complex has been shown to recruit and activate
caspase-8 independent of FADD and induce apoptosis after
p53 activation (25). It is of note that the C-terminal trun-
cated IGFBP-3R mutant shows no interaction with
caspase-8, thus strongly suggesting that caspase-8 interacts
with the cytoplasmic tail of IGFBP-3R (data not shown).
Taken together, we speculate that IGFBP-3R exists as a com-
plex with caspase-8 at the resting stage and IGFBP-3 binding
to IGFBP-3R may facilitate dimerization/oligomerization of
IGFBP-3R, resulting in proximity-induced activation of the
initiator caspase-8 (43).
In summary, we cloned IGFBP-3R, a novel IGFBP-3 death
receptor, and identified the IGFBP-3/IGFBP-3R axis as a
novel caspase-8-dependent cell death signal in human can-
cer cells. Our results not only show suppression of IGFBP-3
and/or IGFBP-3R expression in breast and prostate cancer
but also the anti-tumor effect of IGFBP-3R in vivo.
IGFBP-3R represents a new mammalian cell death receptor
and promotes the utilization of the IGFBP-3/IGFBP-3R axis
for further development of drug screening assays, and diag-
nostic/prognostic and therapeutic methods for cancer
treatment.
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